{
  "id": 1764,
  "text": "The different combinations were not superior to paclitaxel/cisplatin regimen in termes of OS.However, trends in favor of paclitaxel/cisplatin regimen were noted in terms of OR, PFS and response rate.Patients receiving experimental doublets did not report significant differences in health-related quality of life, neuropathy, or pain from those who received the control doublet (paclitaxel/cisplatin).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: The different combinations were not superior to paclitaxel/cisplatin regimen in termes of OS.However, trends in favor of paclitaxel/cisplatin regimen were noted in terms of OR, PFS and response rate.Patients receiving experimental doublets did not report significant differences in health-related quality of life, neuropathy, or pain from those who received the control doublet (paclitaxel/cisplatin)\n\n<question>: ",
  "ChatGPT_response_0": "根据研究结果显示，实验组和对照组在生存率方面并没有显著差异。然而，在疗效和健康相关生活质量方面，对卡侔泰和顺铂组合治疗的趋势更为有利。实验组接受的双联疗法与对照组（卡侔泰和顺铂）相比，在生存期、疗效和健康相关生活质量方面并没有显著差异。",
  "query": "在这项研究中，实验组和对照组在生存率、生存期、疗效和健康相关生活质量方面是否存在显著差异？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在这项研究中，实验组和对照组在生存率、生存期、疗效和健康相关生活质量方面是否存在显著差异？\n\n<reference text>: The different combinations were not superior to paclitaxel/cisplatin regimen in termes of OS.However, trends in favor of paclitaxel/cisplatin regimen were noted in terms of OR, PFS and response rate.Patients receiving experimental doublets did not report significant differences in health-related quality of life, neuropathy, or pain from those who received the control doublet (paclitaxel/cisplatin).\n\n<reply>: ",
  "response": "根据研究结果显示，实验组和对照组在生存率方面并没有显著差异。然而，在疗效和健康相关生活质量方面，对卡侔泰和顺铂组合治疗的趋势更为有利。实验组接受的双联疗法与对照组（卡侔泰和顺铂）相比，在生存期、疗效和健康相关生活质量方面并没有显著差异。"
}